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EDITORIAL
How to improve the early diagnosis of Fabry’s disease?
Fabry’s disease is an X-linked recessive lysosomal disor-
der due to -galactosidase A (-Gal A) deficiency. This
defect is responsible for the gradual accumulation of
glycosphingolipids, mainly globotriaosylceramide (GL3),
in many organs, predominantly in vascular cells, and which
leads to ischemic organ damage. In a recent study per-
formed in Australia, the median age at diagnosis was
28.6 years [1], and similar findings have been documented
in the United States and Europe. Because enzyme replace-
ment therapy (ERT) by human -Gal A has emerged as
a promising means to prevent and remove GL3 deposi-
tion, it is now necessary to make this diagnosis earlier.
Why is an early diagnosis of Fabry’s disease so diffi-
cult? A diagnosis of rare diseases, in general, is not easy
[2]. Acroparesthesias and pain crises, triggered by heat
or fever and often misdiagnosed, are the first symptoms
arising in childhood. The disease was first described in
1898 by two dermatologists, W.A. Anderson and J. Fabry.
Skin angiokeratomas may be profuse, but are sometimes
limited to rare and small lesions, or even absent [3, 4].
Later in life, the diagnosis can be made by ophthalmolo-
gists who discover typical corneal deposits, known as
cornea verticillata, or by neurologists who are confronted
with young male patients with transient ischemic attacks
or cochleovestibular abnormalities, or finally by nephrol-
ogists. Indeed, nephrologists are well placed among those
capable of diagnosing Fabry’s disease. In a man present-
ing with proteinuria during the 3rd or 4th decade, a renal
biopsy examined by an experienced renal pathologist
should be diagnostic by showing typical diffuse vacuola-
tion of glomerular cells, predominantly in podocytes.
Similar changes are found in vascular and tubular cells.
Adequate staining demonstrates that renal cells contain
massive lipid deposits [5, 6]. Electron microscopy con-
firms the diagnosis by showing typical lamellar inclusions
located in lysosomes, but this is not absolutely required
for diagnosis in clinical practice.
Nephrologists are well aware of the clinical heteroge-
neity of genetic diseases: this is true in autosomal-domi-
nant polycystic kidney disease; Alport syndrome may
present without sensorineural hearing loss; and tuberous
sclerosis, without skin lesions, epilepsy, or mental retar-
dation. Renal disease may be the only or prominent
manifestation of Fabry’s disease, as shown by the Japa-
nese study carried out by Nakao et al [7] and published in
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this issue of Kidney International. Indeed, these authors
consecutively screened 514 male hemodialysis patients
for -Gal A deficiency and found 6 patients with low
enzyme activity. These 6 patients had mutations in the
-Gal A gene, confirming the diagnosis of Fabry’s dis-
ease. This cohort, however, is different from American
and European dialysis patients: 366 screened patients
(71%) were classified as having chronic glomerulonephri-
tis, albeit based on rather weak criteria, and only 16 of
them (4%) had a renal biopsy.
Two groups of patients should be differentiated: misdi-
agnosed patients with classic Fabry’s disease (as patient
6, in whom the renal biopsy was initially misinterpreted),
and patients with Fabry’s disease clinically limited to the
kidney, also called “renal variant” (although all had left
ventricular hypertrophy, the mechanism of which can be
questioned in the absence of endomyocardial biopsy).
Conflicting results regarding the prevalence of this renal
variant have been reported. The prevalence rate in three
studies performed in dialysis patients was 0% in The Neth-
erlands [8], 0.47% in the United States [abstract; Desnick
et al, European Symposium on Fabry’s Disease, Athens,
Greece, November 2002], and 0.97% in Japan [7]. In two
other studies, the prevalence rate of Fabry’s disease in
dialysis patients was 0.22% in Italy [abstract; Pagliardini
et al, European Symposium of Fabry’s Disease, Athens,
Greece, November 2002] and 0.49% (2 of 440 males) in
Japan [9]; in the latter study, at least one patient had
classical Fabry’s disease.
These figures are much higher than those reported in
European and American registries (i.e., approximately
0.02%) [10, 11]. Data from large registries and those
from small epidemiologic studies should be cautiously
compared. In addition, the prevalence rate of the renal
variant critically depends on early referral to nephrolo-
gists and to the renal biopsy policies for proteinuric pa-
tients, which may differ from one country to another.
Is it clinically relevant to screen male dialysis patients
for -Gal A deficiency? It should be stressed that the
aim, obviously, is not to perform diagnosis of Fabry’s
renal variant in end-stage renal disease (ESRD), but to
make the diagnosis much earlier in the course of the
renal disease. To achieve this goal, we should improve
nephrologists’ training in rare metabolic and genetic dis-
eases, pay particular attention to patients with a positive
family history of kidney disease (such as in patient 5 in
the Japanese series) [7], and improve the process of early
referral of renal patients to nephrologists. On the other
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hand, nephrologists should be aware that it is possible
to miss or delay diagnosing Fabry’s disease, particularly
in patients without a previously identified family member
and who have only subtle or no systemic symptoms. In
some patients, these abnormalities may be limited to
tortuous conjunctival and retinal vessels [4]. We should
not hesitate to measure -Gal A activity in male renal
patients with no etiologic diagnosis and who have not
undergone renal biopsy. This may also extend to women
with unexplained renal disease. Systemic symptoms are
milder in Fabry’s females than in males, and although
renal failure in women is very rare, 12% of Fabry’s dialysis
patients are females [10, 11]. However, in heterozygous
women, -Gal A activity may be in the normal range.
There is no evidence that ESRD patients with Fabry’s
renal variant will benefit from screening and ERT. Obvi-
ously it is too late to expect beneficial renal effects. In
addition, we have no clinical or histopathologic informa-
tion on the diffusion of vascular GL3 deposits. Do these
patients run a high risk of developing cerebrovascular
and cardiac complications related to GL3 extrarenal de-
posits? On the contrary, ERT should be considered in
dialysis patients with classic Fabry’s disease since two
studies have shown a higher mortality rate in these pa-
tients compared to non-Fabry’s patients [10, 11]. Effec-
tively, ERT could correct this.
Finally, the detection of Fabry’s disease, even in ESRD
patients, may have important consequences for their fami-
lies. Indeed, an investigation should be proposed to these
families to screen members who are at risk after their
informed consent. Hemizygous males and carrier females
can be identified by clinical examination and by using
-Gal A measurement and DNA analysis. Heterozygous
women may receive genetic counseling. Symptomatic man-
agement and ERT should be proposed to affected males
to prevent progression of the kidney disease. This should
be carefully explained to these men who may have no
symptoms and only minimal proteinuria. This strategy
is probably the best way to improve the diagnosis in
Fabry’s disease. Whatever the mode of presentation of
the disease in the propositus (classic versus renal variant),
information should be given to affected families and “ac-
tive” investigation should be offered.
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